Healthcare Triangle, Inc. (Nasdaq: HCTI), a key player in digital transformation solutions for the healthcare and life sciences sectors, has successfully secured the Nasdaq Hearings Panel's approval for the continued listing of its securities. This decision comes after the company addressed a Public Interest Concern raised by Nasdaq's Listing Qualifications Department, demonstrating compliance with the shareholders' equity rule and receiving a continued listing exception to rectify previous deficiencies.
The Panel's approval is contingent upon Healthcare Triangle executing a reverse stock split by August 8, 2025, to meet the Bid Price Rule requirements and maintaining a $1 closing bid price for at least twenty consecutive trading days by September 5, 2025. These steps are crucial for the company to ensure long-term compliance and stability on the Nasdaq exchange.
Dave Rosa, Chairman of the Board of Directors at HCTI, expressed gratitude for the Panel's decision, highlighting the importance of maintaining the listing for current and prospective investors. Rosa emphasized the company's commitment to advancing its mission through strategic growth initiatives, leveraging cloud technologies, AI-driven analytics, and secure data platforms to empower healthcare organizations.
This development is significant for the healthcare technology industry, as it underscores the importance of regulatory compliance and financial stability for companies operating in this space. For investors, Healthcare Triangle's continued listing on Nasdaq provides assurance of the company's commitment to meeting market standards and its potential for sustainable growth in the evolving healthcare technology landscape.
